Metabolic Therapy for Neurodegeneration

📖 Wiki Page

therapeutic768 wordssynced 2026-04-02

Metabolic Therapy for Neurodegeneration

Overview

flowchart TD Metabolic_Therapy_for_Neurodeg["Metabolic Therapy for Neurodegeneration"] Metabolic_Therapy_for_Neurodeg["table"] Metabolic_Therapy_for_Neurodeg -->|"related to"| Metabolic_Therapy_for_Neurodeg style Metabolic_Therapy_for_Neurodeg fill:#81c784,stroke:#333,color:#000 Metabolic_Therapy_for_Neurodeg["class"] Metabolic_Therapy_for_Neurodeg -->|"related to"| Metabolic_Therapy_for_Neurodeg style Metabolic_Therapy_for_Neurodeg fill:#81c784,stroke:#333,color:#000 Metabolic_Therapy_for_Neurodeg["infobox"] Metabolic_Therapy_for_Neurodeg -->|"related to"| Metabolic_Therapy_for_Neurodeg style Metabolic_Therapy_for_Neurodeg fill:#81c784,stroke:#333,color:#000 style Metabolic_Therapy_for_Neurodeg fill:#4fc3f7,stroke:#333,color:#000

...

Metabolic Therapy for Neurodegeneration

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Metabolic Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">AC-1202 (AXONA)</td>
<td>20-30g daily</td>
</tr>
<tr>
<td class="label">Ketone ester</td>
<td>25-50g daily</td>
</tr>
<tr>
<td class="label">MCT oil</td>
<td>20-60g daily</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT00670146</td>
<td>Ketogenic diet</td>
</tr>
<tr>
<td class="label">NCT02531438</td>
<td>MCT oil (Axona)</td>
</tr>
<tr>
<td class="label">NCT03400124</td>
<td>Ketone ester</td>
</tr>
<tr>
<td class="label">NCT04237411</td>
<td>Fasting mimetic</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT03963206</td>
<td>Ketogenic diet</td>
</tr>
<tr>
<td class="label">NCT05237505</td>
<td>MCT supplementation</td>
</tr>
<tr>
<td class="label">NCT05485640</td>
<td>Metabolic modulator</td>
</tr>
</table>

Metabolic therapy encompasses therapeutic approaches that target metabolic dysfunction in neurodegenerative diseases. These strategies aim to improve brain energy metabolism, enhance mitochondrial function, and correct metabolic deficits that contribute to neuronal dysfunction and death. Key approaches include ketogenic diets, metabolic modulators, glucose metabolism enhancers, and fasting mimetics. This therapy is particularly relevant for Alzheimer's disease (AD) and Parkinson's disease (PD), both of which exhibit well-documented metabolic impairments. [@henderson2009]

Mechanism of Action

Brain Energy Metabolism in Neurodegeneration

Neurodegenerative diseases are characterized by impaired cerebral glucose metabolism: [@krikorian2012]

Alzheimer's Disease: Regional brain hypometabolism (especially in posterior cingulate and hippocampus) precedes clinical symptoms by decades. Insulin resistance and impaired glucose transport contribute to energy deficits.
Parkinson's Disease: Complex I deficiency in mitochondria leads to impaired oxidative phosphorylation and ATP depletion in dopaminergic [neurons](/entities/neurons).

Metabolic Therapy Mechanisms

Ketone Utilization: Provide alternative fuel (β-hydroxybutyrate) to glucose-deficient neurons

Mitochondrial Function: Enhance electron transport chain efficiency and ATP production

Insulin Sensitization: Improve insulin signaling and glucose uptake in the brain

Oxidative Stress Reduction: Decrease [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) production

Neuroinflammation Modulation: Reduce inflammatory responses through metabolic pathways

[Autophagy](/entities/autophagy) Enhancement: Activate metabolic pathways that clear misfolded proteins

Therapeutic Approaches

Ketogenic Diet and Ketone Supplementation

The ketogenic diet (KD) mimics fasting metabolism by shifting energy production from glucose to ketone bodies: [@pawelzik2022]

Classic Ketogenic Diet: 70-80% fat, 15-20% protein, 5-10% carbohydrate
Medium-Chain Triglyceride (MCT) Oil: Directly produces ketones in the liver
Exogenous Ketones: Beta-hydroxybutyrate (BHB) supplements

Metabolic Modulators

Dichloroacetate (DCA): Activates pyruvate dehydrogenase complex
Metformin: AMPK activator; improves insulin sensitivity
Thiazolidinediones: PPAR-γ agonists for metabolic regulation

Fasting and Fasting Mimetics

Intermittent Fasting: 16:8 or 5:2 protocols
Caloric Restriction: 20-30% reduction in daily calories
Rapamycin: [mTOR](/mechanisms/mtor-signaling-pathway) inhibitor with fasting-like effects
Resveratrol: SIRT1 activator

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

Key Findings

Ketogenic interventions show consistent cognitive/motor improvements
Benefits may be more pronounced in patients without APOE4 allele
Adherence is challenging; dropout rates of 20-40% in studies
Metabolic biomarkers (ketone levels, glucose metabolism) correlate with clinical response

Metabolic Biomarkers for Patient Selection

Effective patient selection requires metabolic profiling:

Fasting Ketone Levels: Baseline β-hydroxybutyrate < 0.3 mM indicates potential responsiveness

Insulin Sensitivity: HOMA-IR score for metabolic flexibility

[APOE](/proteins/apoe) Status: APOE4 carriers may respond less to glucose-based therapies

Brain Glucose Metabolism: FDG-PET showing hypometabolism patterns

Ketone Response Test: Measure BHB levels after MCT challenge

Safety and Considerations

Ketogenic Diet Risks

Hyperlipidemia: Monitor cholesterol and triglycerides
Kidney Stones: Increased risk; maintain hydration
Nutrient Deficiencies: Supplement vitamins and minerals
Acidosis: Rare in adults; monitor pH and electrolytes

Contraindications

Pancreatitis
Liver failure
Severe renal disease
History of eating disorders
Porphyria

External Links

[PubMed: Metabolic Therapy Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=ketogenic+alzheimer+parkinson)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[Charlie Foundation - Ketogenic Diet Resources](https://charliefoundation.org/)

References

[Henderson et al., Study of the Ketogenic Agent AC-1202 (2009) (2009)](https://doi.org/10.1016/j.nut.2009.04.007)

[Krikorian et al., Ketogenic diet for MCI (2012) (2012)](https://doi.org/10.1007/s12603-012-0083-3)

[Pawelzik et al., Ketogenic diet in Parkinson's disease (2022) (2022)](https://doi.org/10.1002/mds.29065)

[Cunnane et al., Brain energy metabolism in AD (2020) (2020)](https://doi.org/10.1016/j.tics.2020.01.011)

[Van der Auwera et al., Ketogenic diet effects on neurodegeneration (2005) (2005)](https://doi.org/10.1016/j.neurobiolaging.2005.03.010)

[Freeman et al., Ketogenic diet in neurological disorders (2014) (2014)](https://doi.org/10.1016/S1474-4422(14)

[Mattson et al., Energy intake and excitability (2018) (2018)](https://doi.org/10.1016/j.neuron.2018.01.008)

Unknown, NCT03963206 Clinical Trial (n.d.)

[Phillips et al., Low-carbohydrate diets for AD (2018) (2018)](https://doi.org/10.1186/s13195-018-0395-5)

[Taylor et al., Metabolic therapy for PD (2021) (2021)](https://doi.org/10.1002/mds.28466)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Metabolic Therapy for Neurodegeneration

Metabolic Therapy for Neurodegeneration

Overview

Metabolic Therapy for Neurodegeneration

Overview

Mechanism of Action

Brain Energy Metabolism in Neurodegeneration

Metabolic Therapy Mechanisms

Therapeutic Approaches

Ketogenic Diet and Ketone Supplementation

Metabolic Modulators

Fasting and Fasting Mimetics

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

Key Findings

Metabolic Biomarkers for Patient Selection

Safety and Considerations

Ketogenic Diet Risks

Contraindications

See Also

External Links

References

Related Hypotheses